LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | Neratinib | 1.11 | uM | LJP5 | 72 | hr | 1389 | 3862 | 5905 | 0.6527 | 0.6278 |
| MCF7 | Neratinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 3216 | 5905 | 0.5449 | 0.4953 |
| MCF7 | Neratinib | 10 | uM | LJP5 | 72 | hr | 1389 | 2041 | 5905 | 0.3462 | 0.2026 |
| MCF7 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 1389 | 3786 | 5445 | 0.6951 | 0.6611 |
| MCF7 | JW-7-24-1 | 0.12 | uM | LJP6 | 72 | hr | 1389 | 3595 | 5445 | 0.6587 | 0.6149 |
| MCF7 | JW-7-24-1 | 0.37 | uM | LJP6 | 72 | hr | 1389 | 3060 | 5445 | 0.5620 | 0.4891 |
| MCF7 | JW-7-24-1 | 1.11 | uM | LJP6 | 72 | hr | 1389 | 2439 | 5445 | 0.4480 | 0.3289 |
| MCF7 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 1389 | 2028 | 5445 | 0.3715 | 0.2075 |
| MCF7 | JW-7-24-1 | 10 | uM | LJP6 | 72 | hr | 1389 | 1059 | 5445 | 0.1942 | -0.1308 |
| MCF7 | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 3839 | 5905 | 0.6494 | 0.6252 |
| MCF7 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 1389 | 1513 | 5445 | 0.2774 | 0.0419 |
| MCF7 | Dasatinib | 0.12 | uM | LJP5 | 72 | hr | 1389 | 1822 | 5905 | 0.3085 | 0.1385 |
| MCF7 | Dasatinib | 0.12 | uM | LJP6 | 72 | hr | 1389 | 1097 | 5445 | 0.2016 | -0.1137 |
| MCF7 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1389 | 1080 | 5905 | 0.1832 | -0.1136 |
| MCF7 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 1389 | 1028 | 5445 | 0.1886 | -0.1434 |
| MCF7 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 1389 | 937 | 5905 | 0.1588 | -0.1718 |
| MCF7 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 1389 | 1026 | 5445 | 0.1885 | -0.1433 |
| MCF7 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 1011 | 5905 | 0.1713 | -0.1411 |
| MCF7 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1389 | 1046 | 5445 | 0.1919 | -0.1358 |
| MCF7 | Dasatinib | 10 | uM | LJP5 | 72 | hr | 1389 | 1168 | 5905 | 0.1977 | -0.0803 |
| MCF7 | Dasatinib | 10 | uM | LJP6 | 72 | hr | 1389 | 832 | 5445 | 0.1527 | -0.2302 |
| MCF7 | Tozasertib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 1560 | 5905 | 0.2644 | 0.0573 |
| MCF7 | Tozasertib | 0.12 | uM | LJP5 | 72 | hr | 1389 | 1514 | 5905 | 0.2565 | 0.0422 |
| MCF7 | Tozasertib | 0.37 | uM | LJP5 | 72 | hr | 1389 | 1457 | 5905 | 0.2472 | 0.0234 |
| MCF7 | Tozasertib | 1.11 | uM | LJP5 | 72 | hr | 1389 | 1626 | 5905 | 0.2752 | 0.0774 |